US Bancorp DE lowered its stake in shares of PAREXEL International Corporation (NASDAQ:PRXL) by 62.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,764 shares of the medical research company’s stock after selling 31,373 shares during the period. US Bancorp DE’s holdings in PAREXEL International Corporation were worth $1,630,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Capstone Asset Management Co. increased its position in PAREXEL International Corporation by 3.8% in the first quarter. Capstone Asset Management Co. now owns 4,409 shares of the medical research company’s stock valued at $278,000 after buying an additional 160 shares during the last quarter. Clinton Group Inc. bought a new position in PAREXEL International Corporation during the first quarter valued at about $3,682,000. Legato Capital Management LLC increased its position in PAREXEL International Corporation by 6,211.0% in the first quarter. Legato Capital Management LLC now owns 92,393 shares of the medical research company’s stock valued at $1,464,000 after buying an additional 90,929 shares during the last quarter. Macquarie Group Ltd. bought a new position in PAREXEL International Corporation during the fourth quarter valued at about $789,000. Finally, LSV Asset Management increased its position in PAREXEL International Corporation by 43.9% in the first quarter. LSV Asset Management now owns 380,751 shares of the medical research company’s stock valued at $24,029,000 after buying an additional 116,200 shares during the last quarter. 95.90% of the stock is currently owned by institutional investors and hedge funds.

Shares of PAREXEL International Corporation (NASDAQ:PRXL) traded down 0.06% during trading on Friday, reaching $87.48. 916,392 shares of the company’s stock were exchanged. The stock has a 50 day moving average price of $86.66 and a 200-day moving average price of $73.05. The stock has a market capitalization of $4.44 billion, a price-to-earnings ratio of 38.45 and a beta of 0.79. PAREXEL International Corporation has a 52 week low of $51.16 and a 52 week high of $87.86.

PAREXEL International Corporation (NASDAQ:PRXL) last issued its quarterly earnings data on Wednesday, May 3rd. The medical research company reported $0.74 EPS for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. The firm had revenue of $529.30 million for the quarter, compared to analysts’ expectations of $529.38 million. PAREXEL International Corporation had a net margin of 5.12% and a return on equity of 28.68%. The firm’s revenue was up .4% on a year-over-year basis. During the same period in the prior year, the company earned $0.89 EPS. Analysts predict that PAREXEL International Corporation will post $3.24 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “PAREXEL International Corporation (NASDAQ:PRXL) Position Reduced by US Bancorp DE” was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/05/parexel-international-corporation-nasdaqprxl-position-reduced-by-us-bancorp-de.html.

Several equities analysts have recently weighed in on PRXL shares. Credit Suisse Group reissued a “neutral” rating and issued a $83.00 price target (up from $65.00) on shares of PAREXEL International Corporation in a research note on Tuesday, June 6th. Evercore ISI raised shares of PAREXEL International Corporation from an “in-line” rating to an “outperform” rating and set a $85.00 price target on the stock in a research note on Monday, May 15th. Zacks Investment Research downgraded shares of PAREXEL International Corporation from a “hold” rating to a “sell” rating in a research note on Saturday, May 6th. Mizuho raised their price target on shares of PAREXEL International Corporation from $66.00 to $75.00 and gave the stock a “buy” rating in a research note on Tuesday, May 30th. Finally, BidaskClub downgraded shares of PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $74.70.

About PAREXEL International Corporation

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.